The radioligand 177Lu-PSMA-617 showed significant results in patients with metastatic castration-resistant prostate cancer (mCRPC). According to Marcel Tolentino de Rezende, an oncologist at Oncocentro Belo Horizonte, a clinic of the Oncoclínicas Group in Minas Gerais, the drug is a small molecule targeted to the prostate-specific membrane antigen (PSMA) linked to a radiation-emitting radionuclide (lutetium 177). beta that showed activity in a phase 2 study: “Therefore, it is a personalized target drug”, he says.
In a study that included 200 men with this neoplasm profile and already treated with docetaxel, LuPSMA showed promise as an alternative therapy to cabazitaxel, with significantly greater activity. After disease progression with docetaxel, PSMA-targeted radionuclide therapy reduced the risk of disease progression or death by 37%. In the present study, patients treated with PSMA-617 (LuPSMA), labeled with lutetium-177, had lower toxicity and better quality of life compared to those who received cabazitaxel.
For Nicole Machado Rossi Monteiro, an oncologist at the Nucleus of Hematology and Oncology, clinic of Grupo Oncoclínicas in Minas Gerais, the fact that more than 80% of prostate cancer tumors highly express the phenotypic biomarker PSMA makes it a promising therapeutic target. for radioligand therapy.
Go to our website and read the full article, with all the details of the TheraP study.